ReviewClinical rheumatology2021
Kawasaki disease and influenza-new lessons from old associations.
Review in Clinical rheumatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 18 citations in OpenAlex.
- Influenza Complications in Children: The Experience of a Children's Hospital in Romania and a Comparative Literature Review of Western and Eastern Studies.Diseases (Basel, Switzerland) · 2026Article
- Concurrent infections in children with Kawasaki disease: lessons learned over 26 years.Immunologic research · 2025Article
- Drug-Induced Liver Injury-Pharmacological Spectrum Among Children.International journal of molecular sciences · 2025Review
- Concurrent Coxsackievirus A6 Infection and Kawasaki Disease: A Case Report.Reports (MDPI) · 2024Article
- Decreased incidence of Kawasaki disease in South Korea during the SARS-CoV-2 pandemic.Frontiers in pediatrics · 2024Article
- Kawasaki disease and the environment: an enigmatic interplay.Frontiers in immunology · 2023Review
- Emerging evidence of microbial infection in causing systematic immune vasculitis in Kawasaki disease.Frontiers in microbiology · 2023Review
- Review
- Non-SARS, non-MERS human coronavirus infections and risk of Kawasaki disease: a meta-analysis.Future virology · 2021Review
- What Lies Ahead for Young Hearts in the 21Frontiers in cardiovascular medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kawasaki disease (KD), an enigmatic medium vessel vasculitis, presents as an acute febrile illness predominantly affecting young children. KD appears to be a hyper-inflammatory response elicited by environmental or infectious agents (including respiratory viruses) in genetically predisposed individuals. Numerous reports from the current era of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic have described the occurrence of KD/KD-like illness in close temporal proximity to SARS-CoV-2 infection or exposure. Notably, KD has been reported in association with H
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.